Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Short-term Investments (2016 - 2025)

Syndax Pharmaceuticals has reported Short-term Investments over the past 11 years, most recently at $19.6 million for Q4 2025.

  • Quarterly results put Short-term Investments at $19.6 million for Q4 2025, down 95.32% from a year ago — trailing twelve months through Dec 2025 was $19.6 million (down 95.32% YoY), and the annual figure for FY2025 was $19.6 million, down 95.32%.
  • Short-term Investments for Q4 2025 was $19.6 million at Syndax Pharmaceuticals, down from $319.2 million in the prior quarter.
  • Over the last five years, Short-term Investments for SNDX hit a ceiling of $418.8 million in Q4 2024 and a floor of $115000.0 in Q4 2021.
  • Median Short-term Investments over the past 5 years was $12.9 million (2022), compared with a mean of $119.9 million.
  • Biggest five-year swings in Short-term Investments: soared 239294.78% in 2023 and later plummeted 98.71% in 2025.
  • Syndax Pharmaceuticals' Short-term Investments stood at $115000.0 in 2021, then changed by 0.0% to $115000.0 in 2022, then soared by 239294.78% to $275.3 million in 2023, then soared by 52.12% to $418.8 million in 2024, then tumbled by 95.32% to $19.6 million in 2025.
  • The last three reported values for Short-term Investments were $19.6 million (Q4 2025), $319.2 million (Q3 2025), and $346.6 million (Q2 2025) per Business Quant data.